TrialBreast cancer research and treatment2021

Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.

Ming Shen Dai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.